NEW YORK (GenomeWeb News) – Interleukin Genetics said Friday that it has received notification from the New York  Stock Exchange Alternext that the firm is not in compliance with certain listing criteria.

Specifically, the firm’s stockholders' equity is less than $6 million and it has reported losses from continuing operations and net losses in its five most recent fiscal years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.